Innogenetics and Bio-Rad enter into a non-exclusive licensing agreement for HIV-2 patents
Under the agreement, Innogenetics will be granted a non-exclusive license to Bio-Rad's intellectual property in the field of HIV-2 immunoassays and, consequently, all legal proceedings between Innogenetics, Institut Pasteur, Bio-Rad Pasteur, and Bio-Rad Laboratories b.v. will be terminated. The HIV-2 license granted to Innogenetics covers all territories (except the USA and Canada) and runs until the expiration of the last to expire of the licensed patents.
The proceedings were initiated by the aforementioned parties in 1998 and were related to the Institute Pasteur's European patents EP 239 425 and EP 283 327. Based on these patents, claims were pending against Innogenetics at the Courts of Antwerp and Gent, respectively.
In addition, Bio-Rad will be granted an option to Innogenetics HCV genotyping patents. This option is non-exclusive and covers all territories.
Most read news
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.